DSG Press Releases

DSG’s eCaseLink EDC allowed CeloNova Biosciences to manage subject enrollment and capture data efficiently in the global clinical trial of the COBRA PzF Coronary Stent. DSG handled all aspects of clinical study data management from database setup through lock.DSG's data management team added value to their eCaseLink EDC solution by providing CeloNova Biosciences with clean, timely, and cost-effective deliverables and week-to-week metrics showing their own progress throughout the lifespan of the study,” said Mark Barakat, MD, Senior Director, Medical Affairs at CeloNova.

DSG, INC. ACCELERATES GROWTH WITH OPENING OF NEW OFFICE IN BANGALORE, INDIA

MALVERN, Pa., Bangalore, India, January 2017 — DSG, Inc., leading provider of eClinical technology solutions, data management, professional services and customer support recently opened a new office in Bangalore, India, to accommodate rapid growth and better serve client needs. DSG's Bangalore office will complement its existing facility located in Noida, India. DSG Bangalore’s state-of-the-art facility will occupy a floor in the Prestige Shantiniketan building. The new office space will accommodate over 300 people and support the company’s growth strategy.

ORBUS THERAPEUTICS, INC. SELECTS DSG, INC. FOR EDC & IWRS IN RECURRENT ANAPLASTIC ASTROCYTOMA CLINICAL STUDY

MALVERN, Pa., September 30, 2016 — Orbus Therapeutics, Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, has selected DSG, a leader in electronic data capture (EDC).

SUPERNUS PHARMACEUTIACALS SELECTS DSG FOR EDC AND IWRS PHASE 3 CLINICAL STUDIES

MALVERN, Pa., April 01, 2016, — DSG was selected by Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to provide a fully supported eCaseLink EDC system, including IWRS Web-based Randomization-Clinical Supply, a Central lab and third-party CRO data integration, and data management services for two blinded Phase 3 clinical studies on impulsive aggression in pediatric patients being treated for Attention Deficit/Hyperactivity Disorder (ADHD).

DSG, INC. PARTNERS WITH BEDROCAN CANADA AND TWEED IN A NON-INTERVENTIONAL UNBLINDED STUDY TO EVALUATE QUALITY OF LIFE IN PATIENTS TREATED WITH MEDICAL MARIJUANA

MALVERN, Pa., February 16, 2016,— DSG has teamed up with Canada’s leading licensed producers of medical grade marijuana, Bedrocan Canada Inc. and Tweed Inc., subsidiaries of Tweed Marijuana Inc., to provide EDC and Electronic Patient Reported Outcomes (ePRO) services for the companies’ current large-scale in-country clinical study, the largest of its kind. The primary objective of the study, which is intended to continue for three years, include more than 50 sites, and enroll up to 6,000 patients, is to evaluate the quality of life (QoL) of patients before and after treatment with medical cannabis.

INTEGRIUM ENTERS INTO A MULTI-YEAR ENTERPRISE AGREEMENT WITH DSG, INC.

MALVERN, Pa., May 28, 2015, — DSG announced Integrium has signed an Enterprise Licensing Agreement for DSG’s eCaseLink solutions and services.“After years of using DSG’s highly regarded EDC platform, we’re delighted at the opportunity of being able to offer DSG’s eCaseLink EDC directly to our clients along with the integrated CTMS, Site Payment, Protocol Deviation and Safety System Modules that unify and simplify the logistics of electronic trial management within a single enterprise system. We believe that these unified modules and accompanying cutting-edge features like Risk-Based monitoring not only increase our efficiency, but enable us to provide more comprehensive, cost-effective and selective solutions to our clients,” said David Smith, MD.